Fluidigm Europe has announced that LGC has purchased a Biomark system for genetic analysis for use in its UK laboratories.
The system, with its integrated fluidic circuit (IFC) technology, adds digital PCR to LGC's existing range of capabilities, which includes quantitative PCR, genotyping, gene expression, copy number variation and absolute quantification for sequencing.
Initial LGC work with Fluidigm IFC technology will focus on digital PCR and gene expression opportunities within the company's Research and Technology Division, but further application across the company's three other divisions - LGC Standards, Life and Food Sciences and LGC Forensics - is anticipated.
The Biomark system uses integrated fluidic circuit technology to reduce complexity, improve throughput with nanolitre precision and provide cost savings (less reagent and smaller samples) for high-throughput genotyping applications.
Fluidigm's Biomark 96.96 dynamic array is capable of performing 9,216 simultaneous real-time PCR experiments running gold-standard Taqman assays in nanolitre quantities.
Researching all aspects of digital PCR, from quantification through standardisation and comparing it to other methods used today should help the UK biotech industry be at the forefront of industry.
